<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72241">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01975142</url>
  </required_header>
  <id_info>
    <org_study_id>IC 2013-03</org_study_id>
    <nct_id>NCT01975142</nct_id>
  </id_info>
  <brief_title>Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Bresat Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.</brief_title>
  <official_title>Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Bresat Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with metastatic breast cancer considered HER2 negative are included are screened
      for HER2-amplified circulating tumor cells. If at least HER2-amplified circulating tumor
      cell is detected, patients are treated by T-DM 1 in a single ar phase II with an adaptive
      design.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Tumor response rate to T-DM1 in patients with HER2 amplified circulating tumor cells</measure>
    <time_frame>Until disease progression (estimated duration : 1 year)</time_frame>
    <description>Assessment every 6 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection rate of HER2 amplified circulating tumor cells, heterogeneity rate between circulating tumor cells and correlations with patient characteristics</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical failure rate and reproducibility of HER2 FISH on circulating tumor cells</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between HER2 FISH and immunofluorescence on circulating tumor cells</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (responses and stable diseases)</measure>
    <time_frame>Until disease progression (estimated duration : 1 year)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between treatment efficacy and HER2 FISH results (level of amplification, absolute number and percentage of amplified cells)</measure>
    <time_frame>Until disease progression (estimated duration : 1 year)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in CTC numbers during treatment</measure>
    <time_frame>Until disease progression (estimated duration : 1 year)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating tumor DNA before and during treatment</measure>
    <time_frame>Until disease progression (estimated duration : 1 year)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>Until disease progression (estimated duration : 1 year)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Patients With Metastatic Breast Cancer Considered HER2 Negative on Primary Tumor.</condition>
  <arm_group>
    <arm_group_label>TDM-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab - Emtansine</intervention_name>
    <arm_group_label>TDM-1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion criteria for screening:

          -  Breast adenocarcinoma considered HER2-negative on the primary tumour

          -  A least one metastatic site and/or inoperable loco-regional relapse

          -  Measurable disease (RECIST v1.1)

          -  Age from 18 to 75 years

          -  Performance status of 0-1

          -  Efficient contraceptive in non-menopaused women

        Inclusion criteria for treatment :

          -  At least 1 (Cohort &quot; L &quot;) or 5 (cohort &quot; H &quot;) HER2 amplified CTC

          -  Adequate cardiac function

          -  Adequate hematological and biochemical blood tests

        Exclusion Criteria:

          -  Life expectancy of less than 3 months

          -  Previous history of any other stage III or IV invasive cancer

          -  Male breast cancer

          -  Uncontrolled brain metastases

          -  Significant cumulated exposure to anthracyclins

          -  Current or previous significant history of cardio-vascular/pulmonary disease

          -  Previous use of trastuzumab
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Patricia TRESCA, MD</last_name>
    <phone>+33156245765</phone>
    <email>emmanuelle.bouffier@curie.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Véronique SERVENT, DR</last_name>
    </contact>
    <investigator>
      <last_name>Véronique SERVENT, DR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicole TUBIANA-MATHIEU, DR</last_name>
    </contact>
    <investigator>
      <last_name>Nicole TUBIANA-MATHIEU, dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Val d'Aurelle - P. Lamarque</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gilles ROMIEU, DR</last_name>
    </contact>
    <investigator>
      <last_name>Gilles ROMIEU, DR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Pars</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François-Clément BIDARD, DR</last_name>
      <email>francois-clement.bidard@curie.fr</email>
    </contact>
    <investigator>
      <last_name>François-Clément BIDARD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie - Hôpital René HUGENIN</name>
      <address>
        <city>Saint-cloud</city>
        <zip>SAINT-CLOUD</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Florence LEREBOURS, DR</last_name>
    </contact>
    <investigator>
      <last_name>Florence LEREBOURS, DR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Catherine de Sienne</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alain LORTHOLARY, DR</last_name>
    </contact>
    <investigator>
      <last_name>Alain LORTHOLARY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elisabeth LUPORSI, DR</last_name>
    </contact>
    <investigator>
      <last_name>Elisabeht LUPORSI, DR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 14, 2013</lastchanged_date>
  <firstreceived_date>October 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic breast cancer</keyword>
  <keyword>Primary tumor HER2 negative</keyword>
  <keyword>CTC HER2 positive</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Maytansine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
